| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_90d41c5c08b4cc27008c8d448154a71f |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6811
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6843
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6803
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-07
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-07
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-36 |
| filingDate |
2021-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f5b9dde400ed5a5907a02b79438e9f51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bda2dcc178cd7596d0530015ff2e11ef |
| publicationDate |
2022-08-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2022265844-A1 |
| titleOfInvention |
Dosing regimens for anti-tf-antibody drug-conjugates |
| abstract |
Anti-TF antibody drug conjugate and pharmaceutical compositions comprising the antibody drug-conjugate for use in the treatment of a solid cancer comprising administering to a subject a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an anti-TF antibody drug conjugate once a week for three consecutive weeks followed by a one week resting period without any administration of anti-TF ADC so that each cycle time is 28 days including the resting period. |
| priorityDate |
2015-09-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |